Project Grant HT94252310506
Award Date
9/30/23
Completion Date
9/29/25
Dollars Obligated
$414K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
The University of Southern California (USC) received a $1,992,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, effective September 15, 2025 through September 14, 2028, is for the development of a "Synthetic Immune Receptor for the Treatment of Prostate Cancer". The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
This $1,113,749 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Southern California (USC) supports the development of Synthetic Immune Receptor T (SIR-T) cells targeting the B7-H3 protein for the treatment of renal cancer. The grant, which commenced on September 15, 2023, will fund a 3-year research project to explore this novel immunotherapeutic approach for addressing renal cancer. As a leading private research...
The University of Southern California (USC) was awarded a $915,936 Project Grant from the U.S. Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research to investigate SETD2 deficiency as a therapeutic target to upregulate viral mimicry for treating aggressive clear cell renal cell carcinoma in patients. This award is part of the program's focus on cancer, neurological disorders, and other health...
The University of Southern California will receive $165,000 under a Project Grant award from the Defense Health Agency to investigate using WEE1 inhibitor to convert immune cold tumors into immune hot tumors for aggressive clear cell renal cell carcinoma with SETD2 deficiency. The grant period runs from April 1, 2023 to March 31, 2024. This award falls under the Military Medical Research and Development program (CFDA 12.420) which supports basic, applied, and advanced biomedical research to...
The Department of Defense awarded a $3,166,177 Cooperative Agreement to the University of Southern California (USC) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2023. This funding supports the "Convergent Science Cancer Consortium" project, which aims to transform healthcare for Service Members and the American public through innovative biomedical research on cancer and other disease areas. As part of this effort, USC has sub-awarded...
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $630,000.00 to the University of California, Los Angeles (UCLA) for intravesical nectin4 chimeric antigen receptor T cell therapy research for non-muscle invasive bladder cancer. The award period runs from September 1, 2024 to August 31, 2026. As the prime awardee, UCLA will leverage its facilities, faculty expertise, and administrative capabilities...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...
The federal Project Grant award of $457,185.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a research project led by Clemson University to characterize fallopian tube-derived extracellular vesicles for the discovery of ovarian cancer biomarkers. The 2-year project, running from July 1, 2024 to June 30, 2026, will leverage Clemson University's expertise in areas like cancer research, biomedical engineering, and...
The Defense Health Agency awarded a $5,339,958 Project Grant to the Beckman Research Institute of the City of Hope under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the development of a digital health intervention for self-management and telemonitoring in chimeric antigen receptor (CAR)-T cell therapy. This 4-year research project, running from June 2025 to June 2029, aims to advance medical solutions for the battlefield and transform healthcare for...